These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 20198662)
1. Quantitative proteomics study of breast cancer cell lines isolated from a single patient: discovery of TIMM17A as a marker for breast cancer. Xu X; Qiao M; Zhang Y; Jiang Y; Wei P; Yao J; Gu B; Wang Y; Lu J; Wang Z; Tang Z; Sun Y; Wu W; Shi Q Proteomics; 2010 Apr; 10(7):1374-90. PubMed ID: 20198662 [TBL] [Abstract][Full Text] [Related]
2. The Impact of TIMM17A on Aggressiveness of Human Breast Cancer Cells. Yang X; Si Y; Tao T; Martin TA; Cheng S; Yu H; Li J; He J; Jiang WG Anticancer Res; 2016 Mar; 36(3):1237-41. PubMed ID: 26977020 [TBL] [Abstract][Full Text] [Related]
3. High TIMM17A expression is associated with adverse pathological and clinical outcomes in human breast cancer. Salhab M; Patani N; Jiang W; Mokbel K Breast Cancer; 2012 Apr; 19(2):153-60. PubMed ID: 20972741 [TBL] [Abstract][Full Text] [Related]
4. Efficient isolation and proteomic analysis of cell plasma membrane proteins in gastric cancer reveal a novel differentiation and progression related cell surface marker, R-cadherin. Chen B; Luo QC; Chen JB; Lin LE; Luo MX; Ren HY; Chen PQ; Shi LG Tumour Biol; 2016 Sep; 37(9):11775-11787. PubMed ID: 27029387 [TBL] [Abstract][Full Text] [Related]
5. Comparative membrane proteomics analyses of breast cancer cell lines to understand the molecular mechanism of breast cancer brain metastasis. Peng W; Zhang Y; Zhu R; Mechref Y Electrophoresis; 2017 Sep; 38(17):2124-2134. PubMed ID: 28523741 [TBL] [Abstract][Full Text] [Related]
6. Integrated proteomic and metabolic analysis of breast cancer progression. Shaw PG; Chaerkady R; Wang T; Vasilatos S; Huang Y; Van Houten B; Pandey A; Davidson NE PLoS One; 2013; 8(9):e76220. PubMed ID: 24086712 [TBL] [Abstract][Full Text] [Related]
7. Proteomic Analysis of Urine to Identify Breast Cancer Biomarker Candidates Using a Label-Free LC-MS/MS Approach. Beretov J; Wasinger VC; Millar EK; Schwartz P; Graham PH; Li Y PLoS One; 2015; 10(11):e0141876. PubMed ID: 26544852 [TBL] [Abstract][Full Text] [Related]
8. Biomarker discovery in low-grade breast cancer using isobaric stable isotope tags and two-dimensional liquid chromatography-tandem mass spectrometry (iTRAQ-2DLC-MS/MS) based quantitative proteomic analysis. Bouchal P; Roumeliotis T; Hrstka R; Nenutil R; Vojtesek B; Garbis SD J Proteome Res; 2009 Jan; 8(1):362-73. PubMed ID: 19053527 [TBL] [Abstract][Full Text] [Related]
9. Combined Proteomics and Transcriptomics Identifies Carboxypeptidase B1 and Nuclear Factor κB (NF-κB) Associated Proteins as Putative Biomarkers of Metastasis in Low Grade Breast Cancer. Bouchal P; Dvořáková M; Roumeliotis T; Bortlíček Z; Ihnatová I; Procházková I; Ho JT; Maryáš J; Imrichová H; Budinská E; Vyzula R; Garbis SD; Vojtěšek B; Nenutil R Mol Cell Proteomics; 2015 Jul; 14(7):1814-30. PubMed ID: 25903579 [TBL] [Abstract][Full Text] [Related]
10. Efficient isolation and quantitative proteomic analysis of cancer cell plasma membrane proteins for identification of metastasis-associated cell surface markers. Lund R; Leth-Larsen R; Jensen ON; Ditzel HJ J Proteome Res; 2009 Jun; 8(6):3078-90. PubMed ID: 19341246 [TBL] [Abstract][Full Text] [Related]
11. Quantitative Secretomic Analysis Identifies Extracellular Protein Factors That Modulate the Metastatic Phenotype of Non-Small Cell Lung Cancer. Hu R; Huffman KE; Chu M; Zhang Y; Minna JD; Yu Y J Proteome Res; 2016 Feb; 15(2):477-86. PubMed ID: 26736068 [TBL] [Abstract][Full Text] [Related]
12. Identification of markers associated with highly aggressive metastatic phenotypes using quantitative comparative proteomics. Terp MG; Lund RR; Jensen ON; Leth-Larsen R; Ditzel HJ Cancer Genomics Proteomics; 2012; 9(5):265-73. PubMed ID: 22990106 [TBL] [Abstract][Full Text] [Related]
13. Quantitative proteomic analysis identifies new effectors of FOXM1 involved in breast cancer cell migration. Ye X; Zhang Y; He B; Meng Y; Li Y; Gao Y Int J Clin Exp Pathol; 2015; 8(12):15836-44. PubMed ID: 26884854 [TBL] [Abstract][Full Text] [Related]
14. Mass spectrometry (LC-MS/MS) identified proteomic biosignatures of breast cancer in proximal fluid. Whelan SA; He J; Lu M; Souda P; Saxton RE; Faull KF; Whitelegge JP; Chang HR J Proteome Res; 2012 Oct; 11(10):5034-45. PubMed ID: 22934887 [TBL] [Abstract][Full Text] [Related]
15. Translating Proteomic Into Functional Data: An High Mobility Group A1 (HMGA1) Proteomic Signature Has Prognostic Value in Breast Cancer. Maurizio E; Wiśniewski JR; Ciani Y; Amato A; Arnoldo L; Penzo C; Pegoraro S; Giancotti V; Zambelli A; Piazza S; Manfioletti G; Sgarra R Mol Cell Proteomics; 2016 Jan; 15(1):109-23. PubMed ID: 26527623 [TBL] [Abstract][Full Text] [Related]
16. Identification of differentially secreted biomarkers using LC-MS/MS in isogenic cell lines representing a progression of breast cancer. Mbeunkui F; Metge BJ; Shevde LA; Pannell LK J Proteome Res; 2007 Aug; 6(8):2993-3002. PubMed ID: 17608509 [TBL] [Abstract][Full Text] [Related]
17. Discovery of pathway biomarkers from coupled proteomics and systems biology methods. Zhang F; Chen JY BMC Genomics; 2010 Nov; 11 Suppl 2(Suppl 2):S12. PubMed ID: 21047379 [TBL] [Abstract][Full Text] [Related]
18. A Cai J; Chen J; Huang L; Wang C; Zhang W; Zhou Q; Sun Z Front Genet; 2021; 12():658154. PubMed ID: 34421983 [TBL] [Abstract][Full Text] [Related]
19. LncRNA NEAT1 Silenced miR-133b Promotes Migration and Invasion of Breast Cancer Cells. Li X; Deng S; Pang X; Song Y; Luo S; Jin L; Pan Y Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31344855 [TBL] [Abstract][Full Text] [Related]
20. Identification of ganglioside GM2 activator playing a role in cancer cell migration through proteomic analysis of breast cancer secretomes. Shin J; Kim G; Lee JW; Lee JE; Kim YS; Yu JH; Lee ST; Ahn SH; Kim H; Lee C Cancer Sci; 2016 Jun; 107(6):828-35. PubMed ID: 27002480 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]